Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023:1415:117-123.
doi: 10.1007/978-3-031-27681-1_18.

Preexisting Neutralizing Antibodies against Different Adeno-Associated Virus Serotypes in Humans and Large Animal Models for Gene Therapy

Divya Ail  1 , Deniz Dalkara  2
Affiliations
Review

Preexisting Neutralizing Antibodies against Different Adeno-Associated Virus Serotypes in Humans and Large Animal Models for Gene Therapy

Divya Ail et al. Adv Exp Med Biol. 2023.

Abstract

Gene therapy is a potential cure for several inherited retinal dystrophies, and adeno-associated virus (AAV) has emerged as a vector of choice for therapeutic gene delivery to the retina. However, prior exposure to AAVs can cause a humoral immune response resulting in the presence of antibodies in the serum, which can subsequently interfere with the AAV-mediated gene therapy. The antibodies bind specifically to a serotype but often display broad cross-reactivity. A subset of these antibodies called neutralizing antibodies (NABs) can render the AAV inactive, thereby reducing the efficacy of the therapy. The preexisting NAB levels against different serotypes vary by species, and these variations need to be considered while designing studies. Since large animals often serve as preclinical models to test gene therapies, in this review we compile studies reporting preexisting NABs against commonly used AAV serotypes in humans and large animal models and discuss strategies to deal with NABs.

Keywords: AAV serotypes; Adeno-associated virus; Anti-AAV immune response; Large animal models; Neutralizing antibodies; Retinal gene therapy.

PubMed Disclaimer

References

    1. Adachi K, Dissen GA, Lomniczi A, Xie Q, Ojeda SR, Nakai H. Adeno-associated virus-binding antibodies detected in cats living in the Northeastern United States lack neutralizing activity. Sci Rep. 2020;10(1):1–13. https://doi.org/10.1038/s41598-020-66596-4 . - DOI
    1. Ail D, Ren D, Brazhnikova E, Nouvel-Jaillard C, Bertin S, Mirashrafi SB, Fisson S, Dalkara D. Systemic and local immune responses to intraocular AAV vector administration in non-human primates. Mol Ther Methods Clin Dev. 2022;24(March):306–16. https://doi.org/10.1016/j.omtm.2022.01.011 . - DOI - PubMed - PMC
    1. Greenberg B, Butler J, Felker GM, Felker GM, Ponikowsk P, Zsebo KM. Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure. Gene Ther. 2016;23:313–9. - DOI - PubMed
    1. Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF, Masurier C. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010;21(6):704–12. https://doi.org/10.1089/hum.2009.182 . - DOI - PubMed
    1. Bucher K, Rodríguez-Bocanegra E, Dauletbekov D, Dominik Fischer M. Immune responses to retinal gene therapy using adeno-associated viral vectors – implications for treatment success and safety. Prog Retin Eye Res. 2020;83(August):100915. https://doi.org/10.1016/j.preteyeres.2020.100915 . - DOI - PubMed

LinkOut - more resources